Pharma companies extend drug patent periods through add-on patents

This report highlights how pharmaceutical companies have been using add-on patents to extend drug patent periods from an average of two years to over six years. This practice contributes to maintaining high drug prices by delaying generic competition.

Originally published by arstechnica